MET and glioblastoma: Because GBM is a heterogeneous disease in which drug response can be influenced by different mechanisms, the expression of a single gene (i.e., HGF expression) was not expected to fully account for sensitivity to the drug; recent results from clinical trials have shown that total MET expression levels do not indicate responsiveness to MET inhibitors [15].